Ctcbio Inc. (060590.KQ) Stock
Ctcbio Inc.

Company profile
Ctcbio reported revenue of 123.77 billion KRW for fiscal year 2025, down 14.3% from fiscal year 2024. Its largest business segment, Animal and Human Medicine Sale, brought in 83% of segment revenue in fiscal year 2024; South Korea was the largest region with 99%. Our analysis of its filings shows revenue shrinking from 137.88 billion KRW in fiscal year 2023 to 123.77 billion KRW in fiscal year 2025, 5.3% a year on average. Ctcbio reports about 226 full-time employees.
What stands out
- It returned to a profit in fiscal year 2025, 3.24 billion KRW, after 2 years of net losses (5.22 billion KRW in fiscal year 2024).
Figures from company filings; latest fiscal year ended December 31, 2025.
About Ctcbio Inc.
CTCBIO Inc. provides various pharmaceutical products in South Korea and internationally. The company offers animal and human pharmaceuticals; feed additives and ingredients; and functional food products. It also provides cardiovascular, gastrointestinal, osteoporosis, antibiotic, smoking cessation, antifungal and antiviral, antiepileptic, allergic rhinitis, dermatology and genito-urinory, allergic rhinitis and antihistamine, neuropsychiarty, intestinal disorders, X-ray, diabetes, anti-inflammatory and arthritis, and harmones, as well as CTC covid-19 IgM/IgG combo test, a quick antibody test kit on covid-19. In addition, the company offers coating base/plasticizer/pore former, diluting agents, bonding agents, disintegrating agents, lubricants, solubilizer/biopharma, topicals, APIs, and food/health functional foods, as well as animal drugs, physiological activators, functional enhancers, and disinfectants. CTCBIO Inc. was founded in 1993 and is headquartered in Hwaseong-si, South Korea.
Largest shareholders
- Bionote, Inc.23.04%
- Pharmaresearch Bio Co., Ltd.10.61%
- Young-Sik Cho8.7 %8.70%
- Ctcbio Inc.1.13%
- Min-Ku Lee0.000004 %0.00%
Share of the company, as of September 25, 2026
Leadership
- Sun Cho Chang — CEO & Executive Director, 62
- SinGyu Kim — CEO & Executive Director, 61
- Ho-Yeon Cho — President, 67
- Seong-Rin Kim — President, 67
- Keumho Lee — Executive Director, 52
How much revenue does Ctcbio make?
Ctcbio reported 123.77 billion KRW in revenue for fiscal year 2025, down 14.3% from 144.41 billion KRW in fiscal year 2024.
What is Ctcbio's largest business segment?
Animal and Human Medicine Sale, with 127.63 billion KRW or 83% of segment revenue in fiscal year 2024. Next: Hay Sale (16%) and Health Functional Food Sales (1%).
Where does Ctcbio make most of its revenue?
South Korea: 99% of revenue by region in fiscal year 2024, followed by Overseas (1%).
What companies are similar to Ctcbio?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sinil Pharmaceutical Co., Ltd. (012790.KQ), Daehan Nupharm Co.,Ltd. (054670.KQ), PharmGen Science, Inc. (004720.KS), Ildong Holdings Co., Ltd. (000230.KS).
Has Ctcbio made a profit in recent years?
Net income by fiscal year: FY2021, a loss of 7.32 billion KRW; FY2022, 4.70 billion KRW; FY2023, a loss of 15.59 billion KRW; FY2024, a loss of 5.22 billion KRW; FY2025, 3.24 billion KRW. It reported a net loss in 3 of these 5 years.
Company Information
Contact & Links
Data as of .
How to cite: DataPorium, “Ctcbio Inc. (060590.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/060590.KQ